Kezar Life Sciences Granted FDA Type C Meeting to Discuss New Drug Development
Kezar Life Sciences announced that the FDA Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis. The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory AIH. As part of the briefing package submitted to the FDA, Kezar submitted pharmacokinetic and hepatic safety data analyses from previously conducted clinical trials to support a proposal for parallel AIH and hepatic impairment studies. Kezar also submitted additional safety data and an updated risk-mitigation plan aimed to modify the previous requirement issued from the FDA to require 48-hour in-unit patient monitoring in future AIH studies.
Trade with 70% Backtested Accuracy
Analyst Views on KZR
About KZR
About the author
KZR Secures FDA Type C Meeting to Discuss Zetomipzomib Development
- FDA Meeting Approval: Kezar Life Sciences has received approval from the FDA Division of Hepatology and Nutrition to hold a Type C meeting in Q1, aimed at discussing the development of zetomipzomib for autoimmune hepatitis patients, marking a significant advancement in the company's drug development efforts.
- Clinical Study Plan: The meeting will review a potential global randomized Phase 2b clinical study for patients with relapsed and refractory autoimmune hepatitis, and if approved, it will provide a clear clinical pathway for this new therapy.
- Safety Data Analysis: CEO Chris Kirk stated that additional safety and pharmacokinetic data analysis conducted in response to FDA feedback further supports confidence in zetomipzomib's potential to change the treatment landscape, highlighting the company's commitment to the drug's potential.
- Market Reaction: In pre-market trading on NasdaqCM, Kezar Life Sciences shares fell 2.3% to $6.35, reflecting market caution regarding the progress of the new drug development.
Jefferies Lowers Kezar Life Sciences Rating to Hold and Reduces Price Target to $7
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Kezar Initiates Strategic Review Following FDA Setback on Liver Drug Development
Regulatory Challenges: Kezar Life Sciences is facing difficulties in aligning with the FDA regarding a clinical trial for zetomipzomib aimed at treating autoimmune hepatitis, leading to the cancellation of a scheduled Type C meeting and a requirement for additional studies that could delay future trials by approximately two years.
Strategic Review and Restructuring: The company has initiated a strategic review process with the help of TD Cowen and plans to implement a restructuring plan that includes workforce reductions and cost-containment measures, while also experiencing a significant increase in stock price despite recent challenges.
Everything You Should Know About the Upgrade to Buy for Kezar Life Sciences (KZR)
Kezar Life Sciences Upgrade: Kezar Life Sciences, Inc. (KZR) has received a Zacks Rank #2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which could lead to favorable stock price movements.
Importance of Earnings Estimates: The Zacks rating system emphasizes the correlation between earnings estimate revisions and stock price trends, suggesting that tracking these revisions can be beneficial for investors seeking to make informed decisions.
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
FDA Lifts Clinical Hold: The FDA has lifted the partial clinical hold on Kezar Life Sciences' zetomipzomib for autoimmune hepatitis after a safety assessment, allowing the continuation of its Phase 2a trial.
Focus Shift and Future Plans: Kezar has paused development of zetomipzomib for lupus nephritis to concentrate on AIH, while planning to request the FDA to lift the clinical hold for lupus nephritis based on feedback from an Independent Data Monitoring Committee.
Kezar : FDA Lifts Partial Clinical Hold On Phase 2a Trial Of Zetomipzomib In Autoimmune Hepatitis
FDA Update: Kezar Life Sciences has had the partial clinical hold lifted on its PORTOLA Phase 2a trial for zetomipzomib, a treatment for autoimmune hepatitis (AIH).
Focus Shift: The company has ceased development of zetomipzomib for lupus nephritis and is now concentrating solely on AIH, following a review of safety data from a previous trial.
KZR Secures FDA Type C Meeting to Discuss Zetomipzomib Development
- FDA Meeting Approval: Kezar Life Sciences has received approval from the FDA Division of Hepatology and Nutrition to hold a Type C meeting in Q1, aimed at discussing the development of zetomipzomib for autoimmune hepatitis patients, marking a significant advancement in the company's drug development efforts.
- Clinical Study Plan: The meeting will review a potential global randomized Phase 2b clinical study for patients with relapsed and refractory autoimmune hepatitis, and if approved, it will provide a clear clinical pathway for this new therapy.
- Safety Data Analysis: CEO Chris Kirk stated that additional safety and pharmacokinetic data analysis conducted in response to FDA feedback further supports confidence in zetomipzomib's potential to change the treatment landscape, highlighting the company's commitment to the drug's potential.
- Market Reaction: In pre-market trading on NasdaqCM, Kezar Life Sciences shares fell 2.3% to $6.35, reflecting market caution regarding the progress of the new drug development.
Jefferies Lowers Kezar Life Sciences Rating to Hold and Reduces Price Target to $7
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Kezar Initiates Strategic Review Following FDA Setback on Liver Drug Development
Regulatory Challenges: Kezar Life Sciences is facing difficulties in aligning with the FDA regarding a clinical trial for zetomipzomib aimed at treating autoimmune hepatitis, leading to the cancellation of a scheduled Type C meeting and a requirement for additional studies that could delay future trials by approximately two years.
Strategic Review and Restructuring: The company has initiated a strategic review process with the help of TD Cowen and plans to implement a restructuring plan that includes workforce reductions and cost-containment measures, while also experiencing a significant increase in stock price despite recent challenges.
Everything You Should Know About the Upgrade to Buy for Kezar Life Sciences (KZR)
Kezar Life Sciences Upgrade: Kezar Life Sciences, Inc. (KZR) has received a Zacks Rank #2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which could lead to favorable stock price movements.
Importance of Earnings Estimates: The Zacks rating system emphasizes the correlation between earnings estimate revisions and stock price trends, suggesting that tracking these revisions can be beneficial for investors seeking to make informed decisions.
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
FDA Lifts Clinical Hold: The FDA has lifted the partial clinical hold on Kezar Life Sciences' zetomipzomib for autoimmune hepatitis after a safety assessment, allowing the continuation of its Phase 2a trial.
Focus Shift and Future Plans: Kezar has paused development of zetomipzomib for lupus nephritis to concentrate on AIH, while planning to request the FDA to lift the clinical hold for lupus nephritis based on feedback from an Independent Data Monitoring Committee.
Kezar : FDA Lifts Partial Clinical Hold On Phase 2a Trial Of Zetomipzomib In Autoimmune Hepatitis
FDA Update: Kezar Life Sciences has had the partial clinical hold lifted on its PORTOLA Phase 2a trial for zetomipzomib, a treatment for autoimmune hepatitis (AIH).
Focus Shift: The company has ceased development of zetomipzomib for lupus nephritis and is now concentrating solely on AIH, following a review of safety data from a previous trial.
